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in living conditions and nutrition and availability of 
curative chemotherapy have led to worldwide death 
rates from tuberculosis falling to 18 per 100 000 in 
2010.3 Nevertheless, globally there were an estimated 
8·7 million new cases of tuberculosis in 2011 and 1·4 
million deaths,4 with the greatest burden of disease 
falling in low-income and middle-income countries. 
The large number of people with multidrug-resistant 
tuberculosis is a particular concern—630 000 of 
12 million prevalent cases in 2011.4 
As new diagnostic tests, drugs, and drug regimens 
become available that have the potential to radically 
improve the detection and management of tuberculosis, 
the papers in the Series explore the challenges for 
successful implementation of these interventions. We 
are particularly grateful to Alimuddin Zumla and Marco 
Schito for proposing and guiding the Series, and to the 
many authors and peer reviewers for their contributions.
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Zero deaths from tuberculosis: progress, reality, and hope
 To commemorate World TB Day 2013, The Lancet 
Infectious Diseases is publishing a Series of articles on 
tuberculosis, a disease that has long plagued human 
beings and was declared a global emergency in 1993 
by WHO. At that time, most Mycobacterium tuberculosis 
strains were susceptible to ﬁ rst-line tuberculosis drugs, 
and global control of the disease seemed a realistic 
goal. However, tuberculosis persists as one of the main 
causes of death from infectious disease: in 2011, 8·7 
million incident cases causing 1·4 million deaths were 
estimated.1 Roughly 630 000 cases of multidrug-
resistant (MDR) tuberculosis occur worldwide, and 
extensively drug-resistant (XDR) tuberculosis is now 
reported in 84 countries.1 Although the total global 
burden of tuberculosis is higher today than ever before, 
promising new diagnostic, drug, and vaccine pipelines 
provide hope for improved control of the disease. 
In 2013, insuﬃ  cient rapid, accurate point-of-care 
tuberculosis diagnostic tests, and the widespread 
unavailability of facilities to test for drug resistance, 
remain important impediments to global activities of 
tuberculosis control. In the ﬁ rst article of this Series, 
Stephen Lawn and colleagues2 review recent advances 
in the development of new tuberculosis diagnostics. 
Although the Xpert MTB/RIF assay was rapidly endorsed 
by WHO in 2010 and is deemed a landmark diagnostic 
method, Lawn and colleagues point out the drawbacks 
and challenges facing the rapid roll-out of the assay in 
areas endemic for tuberculosis and HIV. Whether the 
test will accelerate progress towards the Millennium 
Development Goal of tuberculosis control targets is 
uncertain because many implementation issues could 
limit the eﬀ ect of the Xpert MTB/RIF assay. Therefore, 
the urgent need for rapid, accurate, aﬀ ordable, point-
of-care tuberculosis diagnostic tests that are easy to use 
and implement remains a priority.  
Accelerated antimicrobial development has created a 
range of promising new drugs and drug regimens against 
drug-sensitive and drug-resistant tuberculosis, which 
are now under clinical evaluation. Recent approval by 
the US Food and Drug Administration of delamanid for 
use in adults with MDR tuberculosis heralds the ﬁ rst new 
tuberculosis drug on the market since the introduction 
of rifampicin in the 1970s. Tuberculosis biomarkers are 
essential for accelerated development and assessment 
of these new drugs to capture the full eﬀ ects of these 
interventions on clinical outcomes in many prospective, 
randomised clinical trials. In the second article of the 
Series, Robert Wallis and colleagues3 look at the many 
M tuberculosis and human biomarkers. Despite recent 
scientiﬁ c progress, discovery of accurate, clinically useful, 
prognostic biomarkers of tuberculosis remains elusive.   
The increase in non-communicable diseases worldwide, 
and in particular in developing countries, now poses 
a competing factor on the unﬁ nished agenda of 
communicable diseases in developing countries. In the 
third article of the Series, Ben Marais and colleagues4 
warn that a broad holistic approach to health-care 
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delivery is needed. The investigators point out major 
overlaps between non-communicable diseases and 
communicable diseases and justify improved integration 
of tuberculosis and HIV care with services for non-
communicable diseases to enhance the eﬃ  ciency of 
public-health services. In the present global economic 
recession, resources targeted for speciﬁ c diseases 
through vertical funding streams need to be integrated 
more broadly across health-care systems. In the fourth 
article in the Series, William Wells and colleagues5 
recommend the prioritisation of rapid drug-susceptibility 
testing through improved delineation of molecular 
mechanisms of resistance and by the association of 
genetic polymorphisms with drug resistance. The authors 
discuss tuberculosis regimens, diagnostics, and drug-
susceptibility testing and prioritise which future drugs 
to test, how to test them, and the development of new 
well characterised collections of M tuberculosis strains 
for the study of new drug-susceptibility testing assays. 
In low-income settings, surveillance data and modelling 
will help to design appropriate drug-susceptibility testing 
algorithms, assist in regimen change nationally, and 
clinical decision making for individual patients.  
 In the ﬁ fth article, Ibrahim Abubakar and colleagues6 
refer to the rising tide of MDR and XDR tuberculosis in 
eastern Europe, Asia, and Africa as a wake-up call for 
everybody, including governments of high-income 
countries. Most laboratories in countries with a high 
burden of tuberculosis are ill equipped to detect and 
diagnose the extent of drug resistance; therefore, 
most MDR tuberculosis and XDR tuberculosis cases 
are undocumented and unreported. As the history 
of tuberculosis in developed countries has shown, 
sustained investment in tuberculosis control and 
research programmes are needed to have a substantial 
and lasting eﬀ ect. Abubakar and colleagues remind us of 
the urgent need for visionary political leadership to stop 
the rising tide of drug-resistant tuberculosis worldwide.
In the sixth article, Renaud Boulanger and colleagues7 
remind us that although a cure for tuberculosis has 
been available for many decades, the disease remains 
widespread, showing several human and structural 
failures. This paper addresses the role of community 
engagement in collaboration with relevant partners 
who share common goals and interests for tuberculosis 
control. Eﬀ orts to reinvigorate tuberculosis 
diagnostics, drugs, and vaccines worldwide are starting 
to bear fruit and provide hope for the achievement 
of global tuberculosis control targets. In view of the 
expected increase in demand for clinical trial sites in 
the coming years (as new tuberculosis diagnostics, 
drug regimens, and vaccines become available for 
clinical testing), research capacity needs to expand and 
local communities should get more actively involved 
in decision-making processes. Wider integration of 
tuberculosis-control activities presents opportunities 
to explore commonalities and potential synergies with 
other communicable and non-communicable disease 
services without the forfeit of recent gains or the 
compromise of functionality of existing tuberculosis 
and tuberculosis–HIV programmes. The need for 
sustained donor funding and increased political and 
ﬁ nancial commitment from governments of countries 
highy endemic for tuberculosis is greater than ever.  
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Progress and challenges in childhood tuberculosis
The plight of children with tuberculosis is widely 
recognised and is increasingly becoming a priority for 
national tuberculosis control programmes. In 2012, 
WHO attempted for the ﬁ rst time to quantify the 
tuberculosis disease burden in children, estimating there 
to be 490 000 cases and 65 000 deaths in 2011.1 Some 
limitations of this estimation were recognised within 
the WHO report1 (table), such as the assumption that 
the ratio of notiﬁ ed to incident cases is the same for 
children and adults, even though under-reporting of 
child tuberculosis cases is very common. The estimated 
number of children with tuberculosis equates to less 
than 6% of all incident cases (8·7 million), whereas 
estimates from tuberculosis endemic areas suggest 
proportions of 10–15%.2 Furthermore, tuberculosis-
related deaths in children infected with HIV were 
classiﬁ ed as deaths due to HIV (not tuberculosis). 
Additionally, many children who die of common 
disorders such as severe pneumonia and malnutrition 
might have unrecognised tuberculosis.3  
Unfortunately, child tuberculosis data reported by 
national tuberculosis control programmes are often 
incomplete and hampered by restricted diagnostic 
access in most tuberculosis endemic areas.2 Children are 
frequently diagnosed in settings where the accuracy and 
quality of non-microbiological diagnoses is weak and 
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Recent progress Key challenges
Disease burden WHO child TB factsheet 2012; formal estimates 
included in the WHO 2012 global TB report1 
Estimates are highly conservative; poor quality of reported data; children 
excluded from planned prevalence surveys 
Diagnosis
Specimen collection Proven feasibility of induced sputum, nasopharyngeal 
aspirates, and ﬁ ne needle aspiration biopsy 
Optimised use of stool samples and the so-called string test; enhanced 
concentration techniques for paucibacillary disease
MTB detection Roll-out of ﬂ uorescence microscopy; roll-out of Xpert 
MTB/RIF assay
Fluorescence microscopy: insensitive to paucibacillary disease and cannot 
diﬀ erentiate MTB from non-tuberculous mycobacteria. Xpert MTB/RIF: 
cartridge cost, limited availability, needs adequate specimens,  and has 
suboptimal sensitivity in children
Treatment
Drug-susceptible TB New treatment guidance allows use of existing 
quality-assured paediatric formulations
Role of ethambutol is not well deﬁ ned, not contained in ﬁ xed-dose 
combination preparations
Drug-resistant TB Excellent outcomes possible in children with MDR-TB Few children treated in existing MDR treatment programmes; substantial 
side-eﬀ ects, especially ototoxicity with injectable use
TB–HIV co-infection Expanded prevention of mother to child transmission 
programmes; early initiation of ART in all HIV-infected 
children
Role of ethambutol in all children with TB–HIV not well deﬁ ned, adds to pill 
burden; need to consider ART adjustment when coadministrating protease 
inhibitors and rifampicin
Pharmacokinetics Comprehensive pharmacokinetic data about ﬁ rst-line 
and second-line TB drugs in children are being collected
Data mostly coming from one geographic location
Prevention
Infection control Greater risk awareness and improved guidelines Poor implementation in most TB endemic areas; frequent mixing of 
susceptible young children and coughing adults in waiting rooms
Preventive therapy Pragmatic guidance using simple symptom-based 
screening
Massive policy–practice gaps; not included in monitoring and assessment 
activities; potential beneﬁ t of continuous isoniazid preventive therapy in 
infants exposed to HIV from TB endemic areas with suboptimal services 
remains unclear; safety and tolerability of new short-course preventive 
therapy options not yet known
TB=tuberculosis. MTB=Mycobacterium tuberculosis. RIF=rifampicin. MDR=multidrug-resistant. ART=antiretroviral therapy.
Table 1: Recent progress and key challenges in childhood tuberculosis
